Denise Faltischek Buys 2,500 Shares of Tilray Brands (NASDAQ:TLRY) Stock

Tilray Brands, Inc. (NASDAQ:TLRY) insider Denise Faltischek acquired 2,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was acquired at an average price of $4.78 per share, for a total transaction of $11,950.00. Following the acquisition, the insider owned 141,285 shares in the company, valued at approximately $675,342.30. The trade was a 1.80% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Tilray Brands Price Performance

TLRY stock opened at $4.43 on Thursday. The business has a 50 day moving average price of $4.62 and a 200 day moving average price of $6.13. The stock has a market cap of $516.32 million, a price-to-earnings ratio of -4.10 and a beta of 1.90. Tilray Brands, Inc. has a fifty-two week low of $3.67 and a fifty-two week high of $23.20. The company has a quick ratio of 1.37, a current ratio of 2.21 and a debt-to-equity ratio of 0.22.

Tilray Brands (NASDAQ:TLRY) last announced its quarterly earnings results on Tuesday, July 28th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.42). Tilray Brands had a negative net margin of 13.11% and a negative return on equity of 7.76%. The company had revenue of $281.71 million during the quarter, compared to analysts’ expectations of $246.30 million. Equities research analysts anticipate that Tilray Brands, Inc. will post -0.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tilray Brands

Several large investors have recently modified their holdings of the company. Tidal Investments LLC raised its stake in Tilray Brands by 15.0% during the 2nd quarter. Tidal Investments LLC now owns 28,971,835 shares of the company’s stock valued at $12,006,000 after acquiring an additional 3,776,410 shares during the last quarter. Millennium Management LLC grew its stake in shares of Tilray Brands by 281.0% in the 3rd quarter. Millennium Management LLC now owns 4,942,319 shares of the company’s stock valued at $8,550,000 after purchasing an additional 3,645,060 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Tilray Brands in the 3rd quarter valued at approximately $5,813,000. Ausdal Financial Partners Inc. acquired a new position in shares of Tilray Brands in the second quarter valued at approximately $939,000. Finally, Scientech Research LLC acquired a new position in shares of Tilray Brands in the third quarter valued at approximately $1,748,000. 9.35% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: CFO Carl Merton purchased 10,000 Tilray shares for approximately $46,200, increasing his direct ownership by 7.71%. The transaction may signal that management believes the stock is undervalued. SEC insider purchase filing
• Positive Sentiment: Director Denise Faltischek purchased 2,500 shares at an average price of $4.78, adding roughly $11,950 to her position. The second insider purchase in the recent news flow provides additional, though relatively modest, support for the shares. Denise Faltischek insider purchase
• Positive Sentiment: TD Securities recently upgraded Tilray to “strong buy,” contributing to the report that the stock traded higher following an analyst upgrade. The action contrasts with other analysts’ more cautious views and could improve short-term sentiment. Tilray analyst upgrade
• Neutral Sentiment: Tilray has attracted attention as a cannabis-sector and Nasdaq Composite watchlist stock. This may increase visibility, but it does not directly change the company’s earnings or operating outlook. Tilray Nasdaq watchlist article
• Negative Sentiment: Despite reporting record fiscal 2026 revenue, analysts questioned how much of the growth was organic because of Tilray’s reliance on acquisitions. The company also recently reported a substantially wider-than-expected quarterly loss, reinforcing concerns about profitability. Tilray fiscal 2026 results analysis
• Negative Sentiment: Coverage highlighting TLRY’s move into penny-stock territory underscores its high volatility and elevated risk. Although larger cannabis companies could benefit as the legal market consolidates, competition and uncertain profitability remain important risks. Tilray penny-stock coverage

Analyst Ratings Changes

Several equities research analysts recently commented on TLRY shares. TD Cowen cut their price target on shares of Tilray Brands from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. TD Securities upgraded shares of Tilray Brands to a “strong-buy” rating in a research note on Friday, July 31st. Wall Street Zen lowered Tilray Brands from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Finally, Weiss Ratings cut Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.